 Roth Capital notes that the FDA cleared Moleculin Biotech Incs NASDAQ:MBRX WP1122 to start a Phase 1 trial in glioblastoma multiforme, which will be in addition to the drugs impending parallel clinical development in COVID-19. Analyst Jonathan Aschoff expects several clinical data updates over the next year, with Moleculin Biotech potentially having six ongoing trials by year-end 2021. 